Grape Skin Extract
A grape skin extract with controlled malvidin-3,5-diglucoside content addresses the need for safer dementia treatments by providing effective neuronal regulation and cognitive enhancement.
Patent Information
- Application Number
- JP2021524759
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-05
- Filing Date
- 2020-05-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-05-22
AI Technical Summary
Current medical treatments for dementia often have significant side effects, while substances derived from biological resources like blueberries and bilberries are safer but research on grapes and grape skins is lacking, necessitating a nerve function regulating effect from grape skin extracts.
A grape skin extract with controlled malvidin-3,5-diglucoside content, along with other anthocyanins, is developed to provide effective neuronal function regulation, including anti-inflammatory and neurotransmitter suppression effects.
The grape skin extract exhibits excellent nerve function regulating effects, protecting nerve cells, improving neurodegenerative diseases, and enhancing cognitive functions such as learning and memory, with minimal side effects.
Smart Images

Figure 0007584103000008 
Figure 0007584103000009 
Figure 0007584103000010
Abstract
Description
[Technical field]
[0001] The present invention relates to a grape skin extract containing a specific amount of malvidin-3,5-diglucoside. [Background technology]
[0002] Anthocyanins are known to exhibit various physiological activities, such as improving visual impairment, antioxidant effects, strengthening blood vessels, anti-inflammatory effects, and antitumor effects, and efforts are being made to utilize biological resources containing anthocyanins.
[0003] For example, blueberry fruit extracts have been reported to be used as anticancer agents (Patent Document 1) and compositions for improving brain function (Patent Document 2). In addition, attempts have been made to suppress the aggregation of amyloid β protein by using anthocyanins contained in bilberries (Non-Patent Document 1). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2003-277271 A [Patent Document 2] JP 2007-145825 A [Non-patent literature]
[0005] [Non-Patent Document 1] MY.Yoshida, et al., "Anthocyanin suppresses the toxicity of Aβ deposits through diversion of molecular forms in vitro and in vivo models of Alzheimer's disease" Nutritional Neuroscience, 2016, Vol.19(1), p.32-42 Summary of the Invention [Problem to be solved by the invention]
[0006] Currently in Japan, the market for dementia treatment drugs continues to expand significantly due to the increase in the number of dementia patients caused by the aging population, and the market size is predicted to expand 1.75 times by 2022 compared to 2013. Generally, medical treatments for dementia have problems such as side effects, which place a heavy burden on patients. On the other hand, substances derived from biological resources have few side effects, are safe, and are suitable for daily or continuous intake. For this reason, there are high hopes for substances derived from biological resources that exhibit neuromodulatory effects.
[0007] With regard to biological resources, as mentioned above, research into anthocyanins has been conducted mainly on blueberries and bilberries, but not enough on grapes and grape skins.
[0008] An object of the present invention is to provide a grape skin extract that exhibits a neuromodulatory effect. [Means for solving the problem]
[0009] The present inventors focused on grapes as a biological resource and conducted research, and found that a specific grape skin extract can exhibit excellent neuromodulatory effects. They also found that the specific grape skin extract has a high content of malvidin-3,5-diglucoside and is unique in its anthocyanin composition. The present invention was made based on the finding that an extract having excellent neuromodulatory effects can be obtained by controlling the content of malvidin-3,5-diglucoside within a specific range when extracting grape skin.
[0010] According to the present invention, there is provided a grape skin extract containing malvidin-3,5-diglucoside in an amount of 15 mg / g or more based on the dry mass. Malvidin-3,5-diglucoside is represented by the following formula (1). [ka] In the grape skin extract, malvidin-3,5-diglucoside may be in a form having a counter anion, such as chloride.
[0011] According to the present invention, there is also provided the above grape extract containing delphinidin-3-glucoside. pericarp The above grape skin extract is further provided, which contains delphinidin-3-glucoside in an amount of 0.01 mole or more and 1.5 moles or less per mole of malvidin-3,5-diglucoside. Delphinidin-3-glucoside is represented by the following formula (2). [ka] In the grape skin extract, delphinidin-3-glucoside may be in a form having a counter anion, such as chloride.
[0012] According to the present invention, there is also provided the above-mentioned grape juice containing malvidin-3-glucoside. pericarp The above grape skin extract is provided, and further provided is the above grape skin extract containing 0.01 mole or more and 1.5 moles or less of malvidin-3-glucoside per mole of malvidin-3,5-diglucoside. Malvidin-3-glucoside is represented by the following formula (3). [ka] In the grape skin extract, malvidin-3-glucoside may be in a form having a counter anion, such as chloride.
[0013] In addition, according to the present invention, J The above grapes contain 3-coumaroyl glucoside. pericarp The extract is further provided with J The above grape skin extract is provided, which contains 0.01 mole or more and 2.0 moles or less of malvidin-3-coumaroylglucoside per mole of malvidin-3,5-diglucoside. Marvi J 3-Coumaroyl glucoside is represented by the following formula (4). [ka] Grape skin extract, Marvi J The 3-coumaroylglucoside may have a counter anion, for example, chloride.
[0014] In addition, according to the present invention, J The above grapes contain 3-coumaroylglucoside-5-glucoside pericarp The extract is further provided with J The above grape skin extract is provided, which contains 0.01 mol or more and 2.0 mol or less of malvidin-3-coumaroylglucoside-5-glucoside per 1 mol of malvidin-3,5-diglucoside. Marvi J Benzene-3-coumaroylglucoside-5-glucoside is represented by the following formula (5). [ka] Grape skin extract, Marvi J The dimethylamino-3-coumaroylglucoside-5-glucoside may be in a form having a counter anion, for example, chloride.
[0015] According to the present invention, there is also provided the above-mentioned grape juice containing resveratrol. pericarp Further, the above grape skin extract is provided, which contains 0.001 mole or more of resveratrol per mole of malvidin-3,5-diglucoside. Resveratrol is represented by the following formula (6). [ka]
[0016] According to the present invention, there is provided any of the above grape skin extracts, wherein the grape skin is the skin of one or more types of grape selected from the group consisting of Vitis Coignetiae, Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis Vinifera, and a hybrid of Vitis flexuosa and Vitis Vinifera.
[0017] The present invention also provides a food composition containing any of the above grape skin extracts, and further provides the above food composition, which is a beverage with an alcohol content of less than 3%.
[0018] The present invention also provides a pharmaceutical composition comprising any one of the above grape skin extracts.
[0019] The present invention also provides a method for producing the above-mentioned grape skin extract, in which a component containing malvidin-3,5-diglucoside is extracted from the grape skin using an organic solvent. Furthermore, the present invention also provides the above-mentioned method for producing a grape skin extract, in which dried grape skin is used as the grape skin, and extraction is performed using an organic solvent containing an acid or a mixed solvent of an organic solvent containing an acid and water. Effect of the Invention
[0020] The grape skin extract of the present invention exhibits an excellent neuromodulatory effect, and according to the present invention, such a grape skin extract can be produced by a simple method. [Brief description of the drawings]
[0021] [Figure 1] 1 is a graph showing the results of the cell survival experiment in Example 1. [Diagram 2]1 is a graph showing the results of an animal experiment in Example 2 (an experiment to confirm anti-inflammatory action; expression of TNF-α (tumor necrosis factor)). [Diagram 3] 1 is a graph showing the results of an animal experiment in Example 2 (an experiment to confirm anti-inflammatory action; expression of IL-6 (interleukin 6)). [Figure 4] 1 is a graph showing the results of an animal experiment in Example 3 (an experiment to confirm the inhibitory effect on the decrease of neurotransmitters; noradrenaline amount). [Diagram 5] 1 is a graph showing the results of an animal experiment in Example 3 (an experiment to confirm the inhibitory effect on the decrease of neurotransmitters; dopamine amount). [Figure 6] 1 is a graph showing the results of the platform test (time to reach the platform) in the animal experiment of Example 4. [Figure 7] 1 is a graph showing the results of a probe test (the number of times the animal crossed the area where the platform was placed) in the animal experiment of Example 4. [Figure 8] 1 is a graph showing the results of a probe test (time spent in the area where the platform was installed) in the animal experiment of Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] The present invention will be described in detail below.
[0023] <Grape skin extract> The grape skin extract of the present invention contains malvidin-3,5-diglucoside in an amount of 15 mg / g or more based on the dry mass.
[0024] (Grape skins) From the viewpoint of the content of malvidin-3,5-diglucoside, the grape skin is preferably the grape skin of Vitis Coignetiae, Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis Vinifera, or a hybrid of Vitis flexuosa and Vitis Vinifera, and more preferably the grape skin of a hybrid of Vitis Coignetiae and Vitis Vinifera, or a hybrid of Vitis flexuosa and Vitis Vinifera. The grape skin can be one or more kinds of grape skin.
[0025] (Anthocyanin composition) The grape skin extract contains malvidin-3,5-diglucoside in a dry mass of 15 mg / g or more. From the viewpoint of regulating nerve function, the malvidin-3,5-diglucoside is preferably 20 mg / g or more, more preferably 25 mg / g or more. The upper limit is not particularly limited, and can be 500 mg / g or less, for example, 100 mg / g.
[0026] The grape skin extract preferably contains delphinidin-3-glucoside, and the content of delphinidin-3-glucoside per 1 mole of malvidin-3,5-diglucoside is preferably 0.01 mole or more, more preferably 0.1 mole or more, from the standpoint of complementarity of the neurological function regulating effects, and is preferably 1.5 moles or less, more preferably 1.0 mole or less, from the standpoint of balance of the neurological function regulating effects.
[0027] The grape skin extract preferably contains malvidin-3-glucoside, and the content of malvidin-3-glucoside is preferably 0.01 mol or more, more preferably 0.03 mol or more, per 1 mol of malvidin-3,5-diglucoside from the standpoint of complementarity of the neurological function regulating effects, and is preferably 1.5 mol or less, more preferably 1.0 mol or less, from the standpoint of balance of the neurological function regulating effects.
[0028] Grape skin extract is Marubi J It may contain maltose-3-coumaroyl glucoside. J The content of malvidin-3-coumaroylglucoside can be 0.01 mol or more and 2.0 mol or less, and preferably 0.05 mol or more and 1.5 mol or less, per 1 mol of malvidin-3,5-diglucoside.
[0029] Grape skin extract is Marubi J It may contain maltose-3-coumaroylglucoside-5-glucoside. J The content of malvidin-3-coumaroylglucoside-5-glucoside can be 0.01 mol or more and 2.0 mol or less, and preferably 0.05 mol or more and 1.5 mol or less, per 1 mol of malvidin-3,5-diglucoside.
[0030] The grape skin extract may contain resveratrol. The content of resveratrol may be 0.001 mol or more, for example, 0.003 mol or more, and may be, for example, 0.100 mol or less, per 1 mol of malvidin-3,5-diglucoside.
[0031] (use) The grape skin extract of the present invention exhibits an excellent neurofunction regulating effect. The neurofunction regulating effect refers to an effect related to prevention of deterioration, maintenance of the current state, recovery, improvement, and prevention of neurofunction. pericarpIt has been suggested that the extract is effective in protecting nerve cells, and also shows anti-inflammatory and neurotransmitter depletion inhibitory effects. Although the detailed mechanism behind this is unclear, it is thought to be the action of components contained in the grape extract, including malvidin-3,5-diglucoside.
[0032] The grape skin extract of the present invention is effective against neurodegenerative diseases related to damage to nerve cells and a decrease in the number of nerve cells, as well as various other symptoms, including anti-aging. Specifically, the grape skin extract of the present invention can be used for the prevention and improvement of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and depression, as well as for the purpose of anti-stress and anti-fatigue. However, the grape skin extract of the present invention can also be used for healthy people, and can be used for the purpose of improving the neural functions of healthy people, such as their learning ability, memory, and reflex response ability. The grape skin extract of the present invention can be used for anti-aging, anti-stress, anti-fatigue, learning ability recovery and improvement, memory recovery and improvement, and reflex response ability recovery and improvement.
[0033] The subjects to which the grape skin extract of the present invention is administered include mammals, such as humans, livestock (horses, cows, pigs, etc.), pets (dogs, cats, etc.), and experimental (test) animals (mice, rats, etc.), preferably humans.
[0034] The dosage of the grape skin extract of the present invention can be appropriately set in consideration of the subject, age, body weight, symptoms, etc., and for example, when administered to humans, the dosage can be 0.2 mg / day or more and 100 mg / day or less per kg of subject body weight, preferably 0.5 mg / day or more, more preferably 1.0 mg / day or more, and preferably 40 mg / day or less, more preferably 20 mg / day or less. When the subject is other than humans, the dosage can be set by appropriately increasing or decreasing the above range. The dosage can be administered once a day or in multiple divided doses. The administration period can be appropriately set in consideration of the subject, age, body weight, symptoms, etc., but continuous use is preferred.
[0035] (Manufacturing method) The grape skin extract can be obtained by extracting components containing malvidin-3,5-diglucoside from grape skin using an organic solvent.
[0036] In the above, dried grape skins can be used as the grape skins. For example, dried grape skins obtained by drying grape skins with warm air or hot air, or freeze-drying the grape skins can be mentioned.
[0037] The extraction is preferably performed using an organic solvent containing an acid or a mixed solvent of an organic solvent containing an acid and water. The acid is preferably a strong acid, such as hydrochloric acid, sulfuric acid, formic acid, trifluoroacetic acid, etc., and is preferably a volatile acid such as hydrochloric acid or formic acid. The organic solvent is preferably a polar solvent, such as methanol, ethanol, acetone, tetrahydrofuran, etc., and is preferably methanol or ethanol. The content of the acid can be appropriately adjusted.
[0038] The extraction can be carried out by homogenizing a solution containing grape skins or using a high-speed high-pressure extraction device. From the viewpoint of extraction efficiency, it is preferable to obtain the above solution by treating under high pressure (for example, 5 MPa to 15 MPa). The obtained solution can be optionally filtered, the filtrate concentrated, and dried (for example, hot air drying or freeze-drying) to obtain a grape skin extract. Alternatively, the obtained solution can be centrifuged, the supernatant collected, a separation solvent added to the supernatant solution to separate an aqueous layer containing the grape skin extract, and the aqueous layer can be concentrated and dried (for example, hot air drying or freeze-drying) to obtain a grape skin extract. The separation solvent is not particularly limited as long as it is an organic solvent that undergoes phase separation with water, and examples of the separation solvent include ethyl acetate, toluene, butyl acetate, hexane, heptane, dichloromethane, and cyclopentyl methyl ether.
[0039] <Food composition> According to the present invention, there is provided a food composition containing the above-mentioned grape skin extract. The food composition may be a functional food, a nutritional supplement, a dietary supplement, a nutritionally enhanced food, a food with functional claims, a food for special dietary uses, a food for specified health uses, or a food with nutrient functions.
[0040] The food composition may contain ingredients acceptable for food manufacturing, such as carriers, excipients (e.g., lactose, sucrose, dextrin, hydroxypropylcellulose, polyvinylpyrrolidone), disintegrants, buffers, emulsifiers, suspending agents, stabilizers, preservatives, and solvents (water, saline, organic solvents such as ethanol). Foods may also contain proteins, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, flavors, and the like.
[0041] The form of the food composition is not particularly limited, and may be a solid, liquid, mixture, suspension, paste, gel, powder, or capsule, and may be a beverage, confectionery, seasoning, side dish, or processed food. The food composition may be a supplement. Among them, a beverage is preferred, and a beverage with an alcohol content of less than 3% is more preferred. The food composition can be obtained by blending the grape skin extract with a food.
[0042] The use of the food composition (target disease or symptom, administration method (administration subject, dosage, period)) can be set in the same manner as for the grape skin extract described above. Specific examples include food compositions for anti-aging, anti-stress, anti-fatigue, recovery and improvement of learning ability, recovery and improvement of memory, and recovery and improvement of reflex reaction ability. The dosage of the grape skin extract can be set to the amount described above for the grape skin extract.
[0043] <Pharmaceutical Composition> The present invention also relates to a pharmaceutical composition containing the grape skin extract. The pharmaceutical composition may be a drug or a quasi-drug.
[0044] The pharmaceutical composition may contain pharma- ceutically acceptable ingredients, such as carriers, excipients (e.g., lactose, sucrose, dextrin, hydroxypropylcellulose, polyvinylpyrrolidone), disintegrants, buffers, emulsifiers, suspending agents, stabilizers, preservatives, and solvents (e.g., water, saline, organic solvents such as ethanol). It may also contain other pharmacological ingredients having pharmacological activity.
[0045] The pharmaceutical composition can be used as a drug or quasi-drug. The pharmaceutical composition may be for oral administration or parenteral administration, and is preferably for oral administration. For oral administration, the pharmaceutical composition may be in the form of a powder, tablet, coating, etc. Tablets For parenteral administration, the formulation may be in the form of a suppository, injection, infusion, ointment, cream, or gel.
[0046] The use of the pharmaceutical composition (target disease and symptoms, administration method (administration subject, dosage, period)) can be set in the same manner as for the grape skin extract. Specific examples include pharmaceutical compositions for anti-aging, anti-stress, anti-fatigue, recovery and improvement of learning ability, recovery and improvement of memory, and recovery and improvement of reflex reaction ability. The dosage of the grape skin extract can be set to the amount described above for the grape skin extract. EXAMPLES
[0047] The present invention will be described in more detail below with reference to examples, although the technical scope of the present invention is not limited to these examples.
[0048] <Sample preparation> The following grape varieties were used in preparing the samples: Fuji no Yume (a hybrid of Ascetic Water (Sanga vine) and Merlot (European grape)) Eight Gold (a hybrid of Ascetic Water (Sanga crane) and Pinot Noir (European grape)) Pione (hybrid) Kaiji (Mixed breed) Muscat Berry A (hybrid)
[0049] The following extraction method was used in sample preparation. ·Extraction method 1 After squeezing grapes to remove the juice, the skins were placed on a stainless steel mesh basket so that they did not touch each other, and a dryer was used to apply hot air at 70°C to obtain dried grape skins. 40 mL of 2% formic acid methanol water (methanol: ultrapure water: formic acid = 70:28:2 (v / v / v)) was added to 6 g of the obtained dried grape skins, and the mixture was stirred (360 rpm) at room temperature under light-shielded conditions for 12 hours to obtain an extract. The obtained extract was filtered using filter paper (Advantec Co., Ltd., quantitative filter paper No. 5A, 110 mm), and the filtered extract solution was concentrated and freeze-dried to obtain a powder of grape skin extract.
[0050] ·Extraction method 2 Grape skins (6-7 grapes) were placed in a stainless steel colander and washed with tap water, taking care not to crush the skins. The washed skins were placed in a thick zip-lock plastic bag and freeze-dried. 1 g of freeze-dried skins was placed in a high-speed, high-pressure extraction device (Nihon Buchi, E-914) and extracted with 1% formic acid methanol. of The extract was extracted three times with methanol (methanol:formic acid = 99:1 (v / v)) under high pressure of 10 MPa to obtain an extract. Approximately 100 mL of the obtained extract was concentrated using a rotary evaporator and freeze-dried to obtain a powder of grape skin extract.
[0051] The powder of the grape skin extract obtained above was dissolved in methanol and subjected to high performance liquid chromatography-mass spectrometry (HPLC / MS) to confirm the amounts of malvidin-3,5-diglucoside, malvidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-coumaroylglucoside, malvidin-3-coumaroylglucoside-5-glucoside, and resveratrol contained in 1 g of the extract powder. The components were identified and quantified using an LC-MS analysis library and compared with the measured values of a standard sample. The results are as follows.
[0052] [Table 1]
[0053] Using the above extracts 1, 4 and 6, the following samples 1 to 4 were prepared. Sample 1: Extract 1 was dissolved in 70% ethanol solution (ethanol:water = 70:30 (v / v)) and the concentration of the extract powder in the resulting solution was adjusted to 100 μg / mL. The concentration of malvidin-3,5-diglucoside was 12.56 μM (calculated in chloride). Sample 2: Extract 4 was dissolved in 70% ethanol solution (ethanol:water = 70:30 (v / v)) and the concentration of the extract powder in the resulting solution was adjusted to 100 μg / mL. The concentration of malvidin-3,5-diglucoside was 1.43 μM (calculated in chloride). Sample 3: Extract 6 was dissolved in 70% ethanol solution (ethanol:water = 70:30 (v / v)) and the concentration of the extract powder in the resulting solution was adjusted to 100 μg / mL. The concentration of malvidin-3,5-diglucoside was 0.80 μM (calculated in chloride). Sample 4: Extract 1 was dissolved in ultrapure water (Milli-Q water) and the concentration of the extract powder in the resulting solution was adjusted to 7.5 mg / mL. The concentration of malvidin-3,5-diglucoside in the solution was 651 μg / mL (calculated in chloride).
[0054] Example 1: Cell survival experiment The following experiment confirmed the inhibitory effect of grape skin extract on neuronal death.
[0055] In a well plate (BD Biocoat, 96 wells), 2 × 10 SH-SY5Y cells (neuronal model cells, ATCC) were added to each well. 5 Cells / mL concentration, 100 μL / well SowingThe cells were seeded and cultured for 24 hours at 37°C in 5% CO. The cell culture medium used was F12 / DMEM medium (Gibco) mixed with 1% non-essential amino acids (Gibco), 15% FBS (Bio West), and 1% penicillin / streptomycin (Lonza). After 24 hours, the culture medium was completely removed using an aspirator, and 100 μL / well of Opti-MEM (Gibco) medium was added, followed by culturing for 24 hours under conditions of 37° C. and 5% CO 2 . Thereafter, the Opti-MEM was completely removed using an aspirator, and 110 μL / well of MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg / mL) mixed with Opti-MEM (MTT reagent:Opti-MEM=1:10) was added, and the cells were cultured for 24 hours under conditions of 37°C and 5% CO2. Next, 100 μL / well of a 10% SDS (sodium dodecyl sulfate) aqueous solution was added, and the cells were cultured for 24 hours under conditions of 37°C and 5% CO2. Thereafter, the absorbance at 570 nm was measured using a microplate reader (Sumitomo Dainippon Pharma Co., Ltd.), the amount of MTT formazan produced was determined, and the relative cell viability was calculated ("Control" in FIG. 1).
[0056] 24 hours after seeding SH-SY5Y cells onto a well plate (BD Biocoat, 96 wells), the culture medium was completely removed using an aspirator, and a mixture of amyloid β protein (Beta-Amyloid 1-42, AnaSpec) mixed with Opti-MEM (Gibco) to a final concentration of 15 μM was added to each well at 100 μL. The cells were cultured for 72 hours at 37°C in 5% CO2 to induce cell death. The MTT formazan production was measured and the relative cell survival rate was calculated in the same manner as above, except that the cells were cultured for 72 hours at 37°C in 5% CO2 to induce cell death (Figure 1, "Aβ").
[0057] 24 hours after seeding SH-SY5Y cells on a well plate (BD Biocoat, number of wells: 96), the culture medium was completely removed using an aspirator, and a mixture of sample 1 mixed with Opti-MEM to a final concentration of 200 μg / mL was added at 90 μL / well and left for 10 minutes. Next, a mixture of amyloid β protein (Beta-Amyloid 1-42, AnaSpec) mixed with Opti-MEM to a concentration of 150 μM was added at 10 μL / well, and the cells were cultured for 72 hours at 37°C and 5% CO2 to induce cell death. The MTT formazan production was measured and the relative cell survival rate was calculated in the same manner as above, except that the cells were cultured for 72 hours at 37°C and 5% CO2 to induce cell death ("Aβ+extract 1" in Figure 1).
[0058] The relative cell viability was calculated in the same manner as above, except that Sample 2 was used instead of Sample 1 ("Aβ+extract 4" in FIG. 1).
[0059] The relative cell viability was calculated in the same manner as above, except that Sample 3 was used instead of Sample 1 ("Aβ+extract 6" in FIG. 1).
[0060] Comparing the “control” and “Aβ” in the figure, the relative cell viability of the latter was significantly lower than that of the former, indicating that cell death was induced by treatment with amyloid β protein. In the figure, "Aβ+ Extract 1" had a significantly higher relative cell viability than "Aβ", indicating that it had an inhibitory effect on cell death. The relative cell viability was equivalent to that of the "Control", suggesting that Extract 1 may have not only an inhibitory effect on cell death, but also an inhibitory effect on cell proliferation. On the other hand, the relative cell viability of "Aβ+ Extract 4" and "Aβ+ Extract 6" was improved compared to "Aβ", but did not reach that of "Aβ+ Extract 1".
[0061] <Example 2: Animal experiment (anti-inflammatory effect confirmation experiment)> The following experiment confirmed the anti-inflammatory effect of grape skin extract.
[0062] The mice used in the experiment and the administration methods are as follows. The rearing conditions other than the administration methods were the same for all groups. Extract administration (SAMP8) group: Sample 4 was orally administered to 10 senescence accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28-30g) at 3.34mL per kg of mouse body weight per day for 38 days ("Senescence accelerated mice + extract 1" in Figures 2 and 3). 3.34mL of sample 4 contains 25mg of extract powder, which is equivalent to 2.17mg of malvidin-3,5-diglucoside. The human equivalent dose of 25 mg extract powder per kg mouse body weight is 2.0 mg extract powder per kg human body weight. Additionally, the human equivalent dose of 2.17 mg malvidin-3,5-diglucoside per kg mouse body weight is 0.18 mg malvidin-3,5-diglucoside per kg human body weight. Water-administered (SAMP8) group: Ultrapure water (Milli-Q (registered trademark) water) in an amount approximately equal to that of Sample 4 administered to the extract-administered (SAMP8) group was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28 to 30 g) for 38 days ("senescence-accelerated mice" in Figures 2 and 3). Water-administered (SAMR1) group: Ultrapure water (Milli-Q (registered trademark) water) in an amount approximately equal to that of Sample 4 administered to the extract-administered (SAMP8) group was orally administered to 10 normal aging mice (SAMR1) (obtained from Japan SLC Co., Ltd., 16 weeks old, weighing 28.5 to 34 g) for 38 days ("normal aging mice" in Figures 2 and 3).
[0063] The details of the animal experiments are as follows: The day after oral administration was completed, the cerebral cortex was removed from each group of mice, RNA was extracted, and the gene expression of TNF-α (tumor necrosis factor) and IL-6 (interleukin 6) was analyzed using real-time PCR. Regarding RNA extraction, ISOGEN reagent (Nippon Gene) was added to the excised cerebral cortex, which was then homogenized using a homogenizer, and RNA was extracted according to the protocol recommended by Nippon Gene (see URL: https: / / www.nippongene.com / siyaku / product / extraction / tds / tds_isogen-rna-dna-protein.pdf). Real-time PCR was performed using a TaqMan Real-Time PCR reagent kit (Thermo Fisher Scientific) in accordance with the protocol recommended by Thermo Fisher Scientific (see URL: https: / / assets.thermofisher.com / TFS-Assets / LSG / manuals / 4304449_TaqManPCRMM_UG.pdf).
[0064] As shown in Figures 2 and 3, a significant increase in the expression of inflammatory cytokines TNF-α and IL-6 was confirmed in the senescence-accelerated mice compared to the normal aging mice. On the other hand, in the senescence-accelerated mice administered the extract, the expression was suppressed to the same extent as in the normal aging mice.
[0065] <Example 3: Animal experiment (test to confirm inhibitory effect on neurotransmitter decrease)> The following experiment confirmed the inhibitory effect of grape skin extract on the decrease of neurotransmitters.
[0066] The mice used in the experiment and the administration methods are as follows. The rearing conditions other than the administration methods were the same for all groups. Extract administration (SAMP8) group: Sample 4 was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28-30 g) at 3.34 mL per kg of mouse body weight per day for 38 days ("Senescence-accelerated mice + extract 1" in Figures 4 and 5). Water-administered (SAMP8) group: Drinking water in an amount approximately equal to that of sample 4 administered to the extract-administered (SAMP8) group was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28-30 g) for 38 days ("senescence-accelerated mice" in Figures 4 and 5). Water administration (SAMR1) group: Drinking water in an amount approximately equal to that of sample 4 administered to the extract administration (SAMP8) group was orally administered to 10 normal aging mice (SAMR1) (obtained from Japan SLC, 16 weeks old, weighing 28.5-34g) for 38 days ("normal aging mice" in Figures 4 and 5).
[0067] The details of the animal experiments are as follows: The day after the oral administration, the cerebral cortex was excised from each group of mice, RIPA Lysis Buffer System (Santa Cruz Biotechnology, Inc.) was added to the cerebral cortex, homogenized using a homogenizer, and protein was extracted. Then, the mixture was centrifuged (10,000×g, 30 min), and the supernatant was collected and noradrenaline and dopamine were quantified. The quantitative determination of noradrenaline was performed using an enzyme-linked immunosorbent assay (ELISA) kit (LDN, BAE-5200). The quantitative determination was performed by measuring the absorbance at 450 nm and dividing the concentration by the known concentration. Norepinephrine From the standard curve using calculation I put it out. Dopamine was quantified using an enzyme-linked immunosorbent assay (ELISA) kit (LDN, BAE-5300). Quantification was performed by measuring the absorbance at 450 nm and comparing it with a standard curve using dopamine with known concentrations. calculation I put it out.
[0068] As shown in Figures 4 and 5, a significant decrease in the neurotransmitters noradrenaline and dopamine was confirmed in the senescence-accelerated mice compared to the normal aging mice. Meanwhile, gene expression in the senescence-accelerated mice administered the extract was at the same level as in the normal aging mice.
[0069] <Example 4: Animal experiment (experiment to confirm the effect of improving learning and memory ability)> The following experiment confirmed the effect of administering grape skin extract on improving the learning and memory abilities of animals.
[0070] The mice used in the experiment and the administration methods are as follows. The rearing conditions other than the administration methods were the same for all groups. Extract administration (SAMP8) group: Sample 4 was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28-30 g) at 3.34 mL per kg of mouse body weight per day for 30 days ("Sensation-accelerated mice + extract 1" in Figures 6 to 8). Water-administered (SAMP8) group: Drinking water in an amount approximately equal to that of sample 4 administered to the extract-administered (SAMP8) group was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks of age, weighing 28-30 g) for 30 days ("senescence-accelerated mice" in Figures 6-8). Water-administered (SAMR1) group: Drinking water in an amount approximately equal to that of sample 4 administered to the extract-administered (SAMP8) group was orally administered to 10 normal aging mice (SAMR1) (obtained from Japan SLC, 16 weeks of age, weighing 28.5-34 g) for 30 days ("normal aging mice" in Figures 6-8). Single-item (M3,5G) administration (SAMP8) group: For reference, malvidin-3,5-diglucoside chloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was orally administered to 10 senescence-accelerated mice (SAMP8) (obtained from Japan SLC, 16 weeks old, weighing 28-30 g) for 30 days at a daily dose of 2.17 mg per kg of mouse body weight ("Sensation-accelerated mice + single item (M3,5G)" in Figures 6 to 8).
[0071] The details of the animal experiments are as follows: The mice in each group were subjected to the Morris water maze test (platform test, probe test) starting the day after the oral administration. A pool with a diameter of 120 cm and a depth of 45 cm was prepared for the Morris water maze. A transparent platform was placed under the water surface of the pool, and 4 markers were placed at equal intervals on the inner wall of the pool.
[0072] Platform Testing: Mice were placed in the pool and the time it took for them to reach the platform was measured. The time limit was 60 seconds, and if they could not reach the platform, the time limit was 60 seconds. After reaching the platform, the mouse was placed on the platform for 15 seconds. This experiment was conducted once a day for seven consecutive days for each mouse in each group. The results are shown in Figure 6.
[0073] Probe Test: On the final day of the test, the platform was removed, and the mouse was placed in the pool in the same manner. The number of times the mouse crossed the area where the platform had been placed and the time it spent in that area were measured within 60 seconds. The results are shown in Figures 7 and 8.
[0074] The platform test evaluates spatial learning and memory using the time it takes for a mouse to reach the platform using visual stimuli such as a landmark as an index. As shown in Figure 6, the time to reach the platform was shortened in normal aging mice (administered water), whereas no shortening of the time to reach the platform was observed in senescence-accelerated mice (administered water). In senescence-accelerated mice administered the extract, a shortening of the time to reach the platform was observed to the same extent as in normal aging mice (administered water). Compared to senescence-accelerated mice administered malvidin-3,5-diglucoside, the shortening of the time to reach the platform was greater in senescence-accelerated mice administered extract 1.
[0075] The probe test evaluates the memory retention ability of mice based on the number of times they crossed the platform and the time spent in the platform. As shown in Figures 7 and 8, the senescence-accelerated mice (administered water) crossed the platform significantly less and spent significantly less time there than the normal aging mice (administered water). The number of times they crossed the platform and the time spent there were observed to be similar to those of the normal aging mice (administered water) in the senescence-accelerated mice administered Extract 1. Compared with the senescence-accelerated mice administered Malvidin-3,5-diglucoside, the senescence-accelerated mice administered the extract crossed the platform more times and spent longer time there.
[0076] As described above, it was confirmed that the administration of the extract of the present invention improved the learning and memory abilities of animals. [Industrial Applicability]
[0077] The grape skin extract of the present invention is effective in protecting nerve cells and exerts a neurofunction regulating effect through said protection, and is expected to improve and prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and depression, and is expected to be developed as a food or medicine such as a health supplement and to expand the related market. Since the grape skin extract of the present invention is derived from a natural product, it is considered to be safe and suitable for daily or continuous intake. Thus, the present invention is highly useful industrially.
Claims
1. A grape skin extract for regulating nerve function contains 20 mg / g or more of malvidin-3,5-diglucoside in dry mass and is administered to a subject at a dosage of 0.2 mg / day or more and 100 mg / day or less per kg of body weight, wherein the grape skin is selected from the group consisting of Vitis Coignetiae, Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis Vinifera, and a hybrid of Vitis flexuosa and Vitis Vinifera. A grape skin extract for regulating nerve function, which is the skin of one or more grapes selected from the group consisting of hybrids of Vitis vinifera.
2. The grape skin extract for regulating nerve function according to claim 1, which contains delphinidin-3-glucoside.
3. 3. The grape skin extract for regulating nerve function according to claim 2, which contains delphinidin-3-glucoside in an amount of 0.01 mol to 1.5 mol per 1 mol of malvidin-3,5-diglucoside.
4. The grape skin extract for regulating nerve function according to any one of claims 1 to 3, which contains malvidin-3-glucoside.
5. The grape skin extract for regulating nerve function according to claim 4, which contains 0.01 mol or more and 1.5 mol or less of malvidin-3-glucoside per 1 mol of malvidin-3,5-diglucoside.
6. The grape skin extract for regulating nerve function according to any one of claims 1 to 5, which contains malvidin-3-coumaroylglucoside.
7. The grape skin extract for regulating nerve function according to claim 6, which contains 0.01 moles or more and 2.0 moles or less of malvidin-3-coumaroylglucoside per mole of malvidin-3,5-diglucoside.
8. The grape skin extract for regulating nerve function according to any one of claims 1 to 7, which contains malvidin-3-coumaroylglucoside-5-glucoside.
9. The grape skin extract for regulating nerve function according to claim 8, which contains 0.01 mol or more and 2.0 mol or less of malvidin-3-coumaroylglucoside-5-glucoside per 1 mol of malvidin-3,5-diglucoside.
10. The grape skin extract for regulating nerve function according to any one of claims 1 to 9, which contains resveratrol.
11. The grape skin extract for regulating nerve function according to claim 10, containing 0.001 mole or more of resveratrol per mole of malvidin-3,5-diglucoside.
12. A food composition comprising the grape skin extract for regulating nerve function according to any one of claims 1 to 11.
13. The food composition for regulating nerve functions according to claim 12, which is a beverage having an alcohol content of less than 3%.
14. A pharmaceutical composition comprising the grape skin extract for regulating nerve function according to any one of claims 1 to 11.
15. A method for producing a grape skin extract according to any one of claims 1 to 11, comprising extracting a component containing malvidin-3,5-diglucoside from grape skin using an organic solvent containing an acid or a mixed solvent of an organic solvent containing an acid and water, As the grape skin, dried grape skin is used, The dried grape skin product is a dried grape skin product of one or more kinds of grapes selected from the group consisting of Vitis Coignetiae, Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis flexuosa, a hybrid of Vitis Coignetiae and Vitis Vinifera, and a hybrid of Vitis flexuosa and Vitis Vinifera; The acid is selected from formic acid and hydrochloric acid, and the organic solvent is selected from methanol and ethanol. A method for producing grape skin extract.
16. A method for producing a grape skin extract as described in claim 15, wherein extraction is performed using methanol containing an acid or a mixed solvent of methanol containing an acid and water.
Citation Information
Patent Citations
A kind of preparation method of 3,5-disaccharide anthocyanins
CN104177460B
Anticancer drug
JP2003277271A
Composition for brain function improvement
JP2007145825A
